MarketPulse — Real-Time Financial News & Market Analysis

Latest News

14,915 articles
Wed, Mar 4
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Actuate Therapeutics to Unveil Cancer Pipeline Expansion at Citizens Conference

Actuate Therapeutics plans to present at the Citizens Life Sciences Conference on March 10, advancing elraglusib tablet into Phase 1/2 oncology trials launching H2 2026.
ACTUcancer therapypipeline expansion
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Zerohash Seeks National Trust Bank Charter to Legitimize Crypto Infrastructure

Crypto infrastructure firm zerohash applies for federal trust bank charter with OCC, aiming to expand regulated stablecoin services for major institutional clients.
MSMSpAMSpEMSpFMSpI+7digital assetsOCC
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Omega Flex Reports 17.7% Profit Decline Amid Housing Slowdown

Omega Flex net income fell 17.7% to $14.8M in 2025 as housing weakness suppressed sales volumes and margins compressed amid development expenses.
OFLXquarterly dividendnet sales decline
BenzingaBenzinga··Business Wire

Penguin Solutions Awards $2.8M in Equity to New Chief Product Officer

Penguin Solutions awards equity package including RSUs and performance-based PSUs to new Chief Product Officer, signaling strategic investment in product leadership.
PENGrestricted stock unitsexecutive compensation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Warburg Pincus, GTCR Sell $25M Sotera Health Shares in Secondary Offering

Private equity firms Warburg Pincus and GTCR offload 25 million shares of $SOHO in secondary offering. Company receives no proceeds but covers expenses.
SHChealthcarestock offering
GlobeNewswire Inc.GlobeNewswire Inc.··Rosen Law Firm

Kyndryl Investors Face April Deadline in Securities Fraud Class Action

Rosen Law Firm reminds Kyndryl investors of April 13, 2026 lead plaintiff deadline in securities fraud class action alleging false financial statements and control failures.
KDsecurities class actionlead plaintiff deadline
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Aecon Wins Arctic Radar Contract as Canada Accelerates NORAD Modernization

Aecon consortium wins major Canadian Arctic radar contract for NORAD modernization, with validation phase starting Q1 2026.
STNArctic Over-the-Horizon Radar ProgramNORAD modernization
The Motley FoolThe Motley Fool··Joe Tenebruso

Ross Stores Surges on Holiday Wins, Raises Shareholder Returns

Ross Stores stock surged 7.98% after beating expectations with 12% holiday sales growth and 21% earnings growth to $2.00 per share, raising dividends 10% and authorizing $2.55B buyback.
ROSTdividend increaseearnings beat
The Motley FoolThe Motley Fool··Neil Patel

Sweetgreen's $5.52 Stock: Can Turnaround Math Justify $10 Valuation?

Sweetgreen stock has collapsed 89% from its $52 IPO price to $5.52, plagued by near-zero growth and $134M annual losses. Reaching $10 requires a turnaround analysts don't foresee.
SGvaluation compressionsame-store sales decline
BenzingaBenzinga··Prnewswire

Veris Residential Declares $0.08 Q1 Dividend as Northeast REIT Eyes Income Appeal

Veris Residential declares $0.08 quarterly dividend payable April 10, 2026, to shareholders of record as of March 31.
VREdividendcash dividend
BenzingaBenzinga··Globe Newswire

Sachem Capital Maintains Dividend Payout as Mortgage REIT Navigates Rate Environment

Sachem Capital declared $0.05 common and $0.484375 preferred dividends payable March 30, 2026, maintaining capital returns amid rate headwinds.
SACHSACHpASCCDSCCESCCF+1quarterly dividenddividend announcement
BenzingaBenzinga··Globe Newswire

CompX International Maintains $0.30 Quarterly Dividend Amid Market Uncertainty

CompX International ($CIX) declares regular $0.30 per share quarterly dividend, payable March 24, 2026 to shareholders of record March 16.
CIXdividendquarterly
BenzingaBenzinga··Globe Newswire

Clarus Maintains Shareholder Returns With $0.025 Quarterly Dividend

Clarus Corporation announces $0.025 quarterly dividend payable March 25, 2026, signaling management confidence in its financial position and commitment to shareholder returns.
CLARdividendquarterly cash dividend
BenzingaBenzinga··Prnewswire

Broadcom Smashes Records With $19.3B Revenue as AI Boom Accelerates Chip Demand

Broadcom reports record Q1 FY2026 revenue of $19.3B, up 29% YoY, with AI revenue surging 106%. Company projects continued acceleration with Q2 guidance of $22B.
AVGOearningsrevenue growth
BenzingaBenzinga··Prnewswire

First United Raises Q2 Dividend to $0.26 Per Share

$FUNC declares quarterly dividend of $0.26 per share, payable May 1, 2026 to shareholders of record April 17.
FUNCcash dividendshareholder returns
The Motley FoolThe Motley Fool··Will Healy

Wall Street's Hidden AI Champions: ASML and Innodata Surge While Investors Sleep

ASML and Innodata, two overlooked AI enablers, posted robust 2025 growth—16% revenue and 27% net income for ASML; 48% revenue growth for Innodata—capturing Wall Street attention amid the AI boom.
TSMINTCASMLINODartificial intelligenceAI stocks
The Motley FoolThe Motley Fool··Brett Schafer

Remitly Stock Soars 26% on Strong Earnings and Bullish 2026 Outlook

Remitly surged 26% in February after posting strong Q4 earnings with 26% revenue growth and record 9% operating margin, despite shares remaining 64% below IPO highs.
RELYearnings growthmarket opportunity
The Motley FoolThe Motley Fool··Rich Smith

Plug Power Surges 23% on Earnings Beat, But Profitability Concerns Linger

Plug Power stock surged 23% on Q4 beat and Wells Fargo's bullish upgrade, but cautious 2026 guidance and delayed profitability raise profitability concerns.
PLUGearnings beatdebt restructuring
BenzingaBenzinga··Eva Mathew

Niagen Bioscience Doubles Profits, Eyes M&A as Stock Trades Well Below Peak

Niagen Bioscience doubled annual profits with $129.4M in sales and 30% revenue growth. CEO signals acquisition hunt and GLP-1-style expansion despite modest 2026 guidance.
NAGEacquisitionsNAD+ supplements
BenzingaBenzinga··Business Wire

Savara to Present MOLBREEVI Progress at Miami Life Sciences Conference

Clinical-stage biotech $SVRA will present at 2026 Citizens Life Sciences Conference, showcasing progress on its Phase 3 rare respiratory disease program.
SVRAclinical-stagebiopharmaceutical